Craig Fraser, CEO of Windtree Therapeutics, Inc. WINT, was recently interviewed by Benzinga. Windtree is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis.  Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, critical in patients experiencing acute cardiac events. Its lead candidate, Istaroxime, is being developed as a first in class treatment for cardiogenic shock and acute heart failure.  Mr. Frasier discussed his company’s progress in developing Istaroxime as well as its recent $12.4 million raise. Learn more here:  Featured photo by Hans Reniers on Unsplash. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.